Henry Su
Event-driven, long only, healthcare

Positive Phase 2 Results For Prana Biotechnology In Huntington's Disease: Behind The Smoke And Mirrors

Executive summary:

  • PBT2 is safe.
  • One serious adverse event occurred secondary to PBT2. A worsening of Huntington's disease symptoms upon its cessation.
  • PBT2 may improve cognition.
  • Efficacy of PBT2 required for approval in Huntington's disease is very low.
  • Approval of PBT2 for Huntington's disease will speed up approval for the larger Alzheimer's dementia indication.
  • IMAGINE trial results for Alzheimer's dementia due to report by the end of March significantly de-risked by the REACH2HD trial.

Prana Biotechnology (NASDAQ:PRAN) has recently released the results of its REACH2HD trial, which it has described as a success.

I have previously written about PBT2 more generally, whereas the focus of this article is to address some issues people have raised about the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details